| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Labastida Ramírez, Alejandro |
| dc.contributor.author | GOLLION, Cedric |
| dc.contributor.author | Stanyer, Emily |
| dc.contributor.author | Dapkute, Austeja |
| dc.contributor.author | Braniste, Diana |
| dc.contributor.author | Caronna, Edoardo |
| dc.date.accessioned | 2023-09-19T09:27:11Z |
| dc.date.available | 2023-09-19T09:27:11Z |
| dc.date.issued | 2023-09-11 |
| dc.identifier.citation | Labastida-Ramírez A, Caronna E, Gollion C, Stanyer E, Dapkute A, Braniste D, et al. Mode and site of action of therapies targeting CGRP signaling. J Headache Pain. 2023 Sep 11;24:125. |
| dc.identifier.issn | 1129-2377 |
| dc.identifier.uri | https://hdl.handle.net/11351/10308 |
| dc.description | Calcitonin; Headache; Migraine |
| dc.description.abstract | Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and/or switching between these therapies are addressed. |
| dc.language.iso | eng |
| dc.publisher | BMC |
| dc.relation.ispartofseries | The Journal of Headache and Pain;24 |
| dc.rights | Attribution 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
| dc.source | Scientia |
| dc.subject | Migranya - Tractament |
| dc.subject | Calcitonina |
| dc.subject.mesh | Migraine Disorders |
| dc.subject.mesh | /drug therapy |
| dc.subject.mesh | Calcitonin Gene-Related Peptide Receptor Antagonists |
| dc.subject.mesh | /therapeutic use |
| dc.title | Mode and site of action of therapies targeting CGRP signaling |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1186/s10194-023-01644-8 |
| dc.subject.decs | trastornos migrañosos |
| dc.subject.decs | /farmacoterapia |
| dc.subject.decs | antagonistas del receptor del péptido relacionado con el gen de la calcitonina |
| dc.subject.decs | /uso terapéutico |
| dc.relation.publishversion | https://doi.org/10.1186/s10194-023-01644-8 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Labastida-Ramírez A] Wolfson Centre for Age Related Diseases, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK. [Caronna E] Unitat de Cefalees, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Gollion C] Department of Neurology, University Hospital of Toulouse, Toulouse, France. [Stanyer E] Wolfson Centre for Age Related Diseases, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK. Nufeld Department of Clinical Neurosciences, Sleep and Circadian Neuroscience Institute, University of Oxford, Oxford, UK. [Dapkute A] Centre of Neurology, Vilnius University, Vilnius, Lithuania. [Braniste D] Institute of Neurology and Neurosurgery, Diomid Gherman, Chișinău, Moldova. State University of Medicine and Pharmacy, Nicolae Testemițanu, Moldova |
| dc.identifier.pmid | 37691118 |
| dc.identifier.wos | 001061857100001 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |
